Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Hodgkin Disease 2Hematologic Neoplasms 2Sezary Syndrome 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Cytomegalovirus Infections 1

Interventions

Valganciclovir 4Blood Specimen Collection 3Valacyclovir 2Polymerase Chain Reaction 2Ganciclovir 2Flow Cytometry 2Cell Count 2letermovir 1Therapeutics 1Stem Cell Transplantation 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Magnetic Resonance Spectroscopy 1Immunologic Techniques 1Gene-Eden-VIR 1Foscarnet 1Antiviral Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cytomegalovirus Infections × letermovir × Clear all
NCT04017962 2025-08-11

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
102 enrolled 13 charts

Cytomegalovirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡